Back to top

Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?

Read MoreHide Full Article

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Amedisys (AMED - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Amedisys is one of 756 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. AMED is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past 90 days, the Zacks Consensus Estimate for AMED's full-year earnings has moved 9.62% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the most recent data, AMED has returned 130.53% so far this year. Meanwhile, the Medical sector has returned an average of 10.94% on a year-to-date basis. As we can see, Amedisys is performing better than its sector in the calendar year.

To break things down more, AMED belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 16 individual companies and currently sits at #90 in the Zacks Industry Rank. On average, stocks in this group have gained 23.97% this year, meaning that AMED is performing better in terms of year-to-date returns.

AMED will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Amedisys, Inc. (AMED) - free report >>

More from Zacks Tale of the Tape

You May Like